SK108496A3 - Pharmaceutical composition and its use to inhibit thrombin formation - Google Patents

Pharmaceutical composition and its use to inhibit thrombin formation Download PDF

Info

Publication number
SK108496A3
SK108496A3 SK1084-96A SK108496A SK108496A3 SK 108496 A3 SK108496 A3 SK 108496A3 SK 108496 A SK108496 A SK 108496A SK 108496 A3 SK108496 A3 SK 108496A3
Authority
SK
Slovakia
Prior art keywords
fibrin
monoclonal antibody
antibody
fibrinogen
specific monoclonal
Prior art date
Application number
SK1084-96A
Other languages
English (en)
Slovak (sk)
Inventor
Paul E Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of SK108496A3 publication Critical patent/SK108496A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1084-96A 1994-02-24 1995-02-21 Pharmaceutical composition and its use to inhibit thrombin formation SK108496A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (1)

Publication Number Publication Date
SK108496A3 true SK108496A3 (en) 1997-10-08

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1084-96A SK108496A3 (en) 1994-02-24 1995-02-21 Pharmaceutical composition and its use to inhibit thrombin formation

Country Status (26)

Country Link
US (1) US5487892A (ja)
EP (1) EP0749320A4 (ja)
JP (1) JPH09509429A (ja)
KR (1) KR970701063A (ja)
CN (1) CN1146157A (ja)
AU (1) AU708897B2 (ja)
BG (1) BG62476B1 (ja)
BR (1) BR9506949A (ja)
CA (1) CA2183953A1 (ja)
CZ (1) CZ246496A3 (ja)
FI (1) FI963288A (ja)
GE (1) GEP20002257B (ja)
HU (1) HUT76536A (ja)
LT (1) LT4192B (ja)
LV (1) LV11784B (ja)
MD (1) MD1521G2 (ja)
MX (1) MX9603602A (ja)
NO (1) NO963497L (ja)
NZ (1) NZ281481A (ja)
PL (1) PL316005A1 (ja)
RU (1) RU2152801C2 (ja)
SG (1) SG53279A1 (ja)
SK (1) SK108496A3 (ja)
TJ (1) TJ301B (ja)
UA (1) UA41984C2 (ja)
WO (1) WO1995022986A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
ES2367032T3 (es) * 2004-12-28 2011-10-27 Sekisui Medical Co., Ltd. Anticuerpo monoclonal anti-fibrina soluble humana y procedimiento de ensayo inmunológico usando el anticuerpo.
CN107115526A (zh) 2011-05-02 2017-09-01 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
BR112015013444B1 (pt) 2012-12-13 2022-11-01 Immunomedics, Inc Uso de um imunoconjugado
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
IL83631A0 (en) * 1986-08-25 1988-01-31 American Biogenetic Sciences Monoclonal antibodies to fibrin
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
EP0413763B1 (en) * 1988-06-13 1996-11-06 American Biogenetic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
EP0749320A1 (en) 1996-12-27
NO963497L (no) 1996-10-16
MD960334A (en) 1997-09-30
SG53279A1 (en) 1998-09-28
EP0749320A4 (en) 1997-06-18
HUT76536A (en) 1997-09-29
MD1521G2 (ro) 2001-03-31
FI963288A0 (fi) 1996-08-23
LT4192B (en) 1997-07-25
FI963288A (fi) 1996-08-23
LV11784A (lv) 1997-06-20
LV11784B (en) 1997-12-20
AU1843495A (en) 1995-09-11
TJ301B (en) 2001-08-06
CZ246496A3 (en) 1997-04-16
NO963497D0 (no) 1996-08-22
LT96140A (en) 1997-03-25
UA41984C2 (uk) 2001-10-15
KR970701063A (ko) 1997-03-17
WO1995022986A1 (en) 1995-08-31
MX9603602A (es) 1997-05-31
BG62476B1 (bg) 1999-12-30
HU9602337D0 (en) 1996-10-28
GEP20002257B (en) 2000-10-25
MD1521F2 (en) 2000-08-31
RU2152801C2 (ru) 2000-07-20
JPH09509429A (ja) 1997-09-22
US5487892A (en) 1996-01-30
CA2183953A1 (en) 1995-08-31
AU708897B2 (en) 1999-08-12
CN1146157A (zh) 1997-03-26
BG100863A (en) 1997-08-29
BR9506949A (pt) 1997-09-23
PL316005A1 (en) 1996-12-23
NZ281481A (en) 1998-07-28

Similar Documents

Publication Publication Date Title
AU2014301041B2 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
EP0420937B1 (en) Therapeutic compositions for the treatment of myocardial infarction
US7754215B2 (en) Antithrombotic therapy with antibodies binding to the A3 domain of von Willebrand factor (VWF)
SK108496A3 (en) Pharmaceutical composition and its use to inhibit thrombin formation
US6251393B1 (en) Conformation-specific anti-von Willebrand Factor antibodies
JPH06184196A (ja) ビトロネクチン由来合成ペプチドおよびそれらを含有する医薬組成物
US20090010934A1 (en) Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
Takahashi et al. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo
US20210189368A1 (en) Recombinant fusion proteins for preventing or treating adhesions of tissues or organs
Edgell et al. Monoclonal antibodies to human fibrin: interaction with other animal fibrins
WO2018089756A1 (en) Targeted anticoagulant
WO2012110843A1 (en) Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema